Cargando…
Clinical benefits of switching to insulin degludec irrespective of previous basal insulin therapy in people with Type 1 or Type 2 diabetes: evidence from a European, multicentre, retrospective, non‐interventional study (EU‐TREAT)
AIMS: To investigate whether the benefits of switching to insulin degludec observed in the European retrospective chart review study EU‐TREAT were dependent on the previous basal insulin used. METHODS: People with Type 1 or Type 2 diabetes were switched to insulin degludec from other basal insulins...
Autores principales: | Knudsen, S. T., Lapolla, A., Schultes, B., Tentolouris, N., Catarig, A.‐M., Wolden, M. L., Siegmund, T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6618263/ https://www.ncbi.nlm.nih.gov/pubmed/31001865 http://dx.doi.org/10.1111/dme.13976 |
Ejemplares similares
-
A European, multicentre, retrospective, non‐interventional study (EU‐TREAT) of the effectiveness of insulin degludec after switching basal insulin in a population with type 1 or type 2 diabetes
por: Siegmund, Thorsten, et al.
Publicado: (2017) -
Switching “Real-World” Diabetes Patients to Degludec from Other Basal Insulins Provides Different Clinical Benefits According to Their Baseline Glycemic Control
por: Tentolouris, Nikolaos, et al.
Publicado: (2019) -
Short-Term Cost-Effectiveness of Switching to Insulin Degludec in Japanese Patients with Type 2 Diabetes Receiving Basal–Bolus Therapy
por: Langer, Jakob, et al.
Publicado: (2019) -
Switching to Degludec From Other Basal Insulins Is Associated With Reduced Hypoglycemia Rates: A Prospective Study
por: Fadini, Gian Paolo, et al.
Publicado: (2019) -
Degludec insulin: A novel basal insulin
por: Kalra, Sanjay, et al.
Publicado: (2011)